Market Closed -
Nasdaq
02:00:00 10/05/2024 am IST
|
5-day change
|
1st Jan Change
|
5.56
USD
|
-10.61%
|
|
+4.32%
|
-47.05%
|
Fiscal Period: June |
2022
|
2023
|
---|
Capitalization
1 |
450.3
|
299.8
|
Enterprise Value (EV)
1 |
434.7
|
288.7
|
P/E ratio
|
-59.5
x
|
-51.1
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
EV / Revenue
|
-
|
-
|
EV / EBITDA
|
-5,82,06,538
x
|
-4,82,75,824
x
|
EV / FCF
|
-16,16,53,517
x
|
-12,68,61,822
x
|
FCF Yield
|
-0%
|
-0%
|
Price to Book
|
26.4
x
|
24.9
x
|
Nbr of stocks (in thousands)
|
13,013
|
13,013
|
Reference price
2 |
34.60
|
23.04
|
Announcement Date
|
31/10/22
|
27/10/23
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-0.8029
|
-1.355
|
-7.468
|
-5.981
|
EBIT
1 |
-0.391
|
-0.8124
|
-1.381
|
-7.618
|
-6.274
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-0.391
|
-0.8124
|
-1.347
|
-7.595
|
-6.062
|
Net income
1 |
-0.391
|
-0.8124
|
-1.347
|
-7.446
|
-5.871
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.0391
|
-0.0812
|
-0.1347
|
-0.5815
|
-0.4512
|
Free Cash Flow
|
-
|
-0.5211
|
-0.2835
|
-2.689
|
-2.276
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
22/03/21
|
29/10/21
|
31/10/22
|
27/10/23
|
Fiscal Period: June |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
1.84
|
2.68
|
3.62
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
-
|
15.6
|
11.1
|
Leverage (Debt/EBITDA)
|
-
|
-3.342
x
|
-2.674
x
|
-
|
-
|
Free Cash Flow
|
-
|
-0.52
|
-0.28
|
-2.69
|
-2.28
|
ROE (net income / shareholders' equity)
|
-
|
36.2%
|
40.5%
|
-116%
|
-41.7%
|
ROA (Net income/ Total Assets)
|
-
|
-134%
|
-202%
|
-51.9%
|
-25.6%
|
Assets
1 |
-
|
0.6059
|
0.6662
|
14.36
|
22.94
|
Book Value Per Share
2 |
-0.1800
|
-0.2700
|
-0.4000
|
1.310
|
0.9200
|
Cash Flow per Share
2 |
0.0200
|
0.0400
|
0.0100
|
0.4900
|
0.1200
|
Capex
|
-
|
0.12
|
-
|
0.78
|
0.03
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/03/21
|
22/03/21
|
29/10/21
|
31/10/22
|
27/10/23
|
|
1st Jan change
|
Capi.
|
---|
| -47.05% | 72.35M | | +17.96% | 44.96B | | +48.77% | 41.85B | | +1.17% | 42.65B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|